Long-acting amylin analogue studied in weight regulation.
Cagrilintide is a long-acting amylin analogue under investigation alone and combined with semaglutide for body-weight research.
Co-activates amylin and calcitonin receptors, slowing gastric emptying and promoting satiety signaling.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
PK/PD characterization of cagrilintide + semaglutide co-administration.
Tolerable PK with additive effects on body weight and glycemic markers.
Dose-finding RCT of weekly cagrilintide vs. placebo and liraglutide 3 mg.
Up to −10.8% weight loss with 4.5 mg dose vs. −3.0% placebo.
Fixed-ratio cagrilintide + semaglutide 2.4 mg combination in T2D.
HbA1c −2.18% and weight −15.6% with combination therapy.
Lyophilized -20°C. Reconstituted: 2–8°C, 28 days.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Cagrilintide is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
